Unsere Publikationen

Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374

Link
https://doi.org/10.3390/vaccines12080911
Tags
Multiple SkleroseNeuroimmunologie
Jahr
2024
Autoren
Ziemssen T, Groth M, Winkelmann VE, Bopp T.
Verlag
Vaccines 2023, 11, 1374. Vaccines. 2024; 12(8):911.
Zum Eintrag

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Link
https://doi.org/10.57264/cer-2023-0161
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.
Verlag
J Comp Eff Res. 2024 Aug 19:e230161.
Zum Eintrag

Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER

Link
https://doi.org/10.1016/j.msard.2024.105812
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Ziemssen T, Posevitz-Fejfár A, Chudecka A, Cepek L, Reifschneider G, Grothe C, Richter J, Wagner T, Müller B, Penner IK.
Verlag
Mult Scler Relat Disord. 2024 Aug 10;90:105812.
Zum Eintrag

Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA

Link
https://doi.org/10.1016/j.nerep.2024.100211
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Yalachkov Y, Akgün K, Ziemssen T.
Verlag
Neuroimmunology Reports. 2024, 5:100211.
Zum Eintrag

Rule-Based DSL for Continuous Features and ML Models Selection in Multiple Sclerosis Research

Link
https://doi.org/10.3390/app14146193
Tags
Multiple SkleroseManagement & ScienceeHealth
Jahr
2024
Autoren
Zhao W, Wendt K, Ziemssen T, Aßmann U.
Verlag
Applied Sciences. 2024; 14(14):6193.
Zum Eintrag

Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis

Link
https://doi.org/10.1016/j.msard.2024.105751
Tags
Multiple SkleroseMS BehandlungManagement & Science
Jahr
2024
Autoren
Papukchieva S, Kim HD, Stratil AS, Magurne E, Jonckheere A, Kahn M, Schneeweiss S, Ziemssen T, Friedrich B.
Verlag
Mult Scler Relat Disord. 2024 Jul 4;88:105751.
Zum Eintrag

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Link
https://doi.org/10.3389/fimmu.2024.1404316
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Höpner L, Proschmann U, Inojosa H, Ziemssen T, Akgün K.
Verlag
Front Immunol. 2024 Jun 13;15:1404316.
Zum Eintrag

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Link
https://doi.org/10.1007/s40120-024-00637-2
Tags
Multiple SkleroseMS Behandlung
Jahr
2024
Autoren
Singer BA, Wray S, Gudesblatt M, Bumstead B, Ziemssen T, Bonnell A, Scaramozza M, Levin S, Shanmugasundaram M, Chen H, Mendoza JP, Lewin JB, Shankar SL.
Verlag
Neurol Ther. 2024 Jun 27.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-